SCHEMBL1825239

SCHEMBL1825239

COC(=O)C(OC(C)=O)c1cccc(OS(=O)(=O)c2ccc(C)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 3/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 3/20 0.43
GAA P10253 2/20 0.43
G6PD P11413 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
ALDH1A1 P00352 3/20 0.41
ENPP2 Q13822 3/20 0.40
HPGD P15428 1/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
DHODH Q02127 1/20 0.40
P2RY2 P41231 2/20 0.39
MAOB P27338 1/20 0.39
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.38
TCF4 P15884 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1826863 0.91 ADRB3 (0.43) GPR17LMNAGAAKMT2AALDH1A1
SCHEMBL1827374 0.90 GPR17 (0.47) GPR17LMNAMAPTGAAG6PD
SCHEMBL1827639 0.90 GPR17 (0.44) GPR17LMNAMAPK1MAPTGAA
SCHEMBL1825373 0.86 KMT2A (0.49) LMNAMAPK1MAPTKMT2AMEN1
SCHEMBL1823402 0.85 GPR17 (0.44) GPR17LMNAMAPTGAAG6PD
SCHEMBL1825862 0.84 ALDH1A1 (0.39) KMT2AALDH1A1
SCHEMBL1825096 0.83 KMT2A (0.45) GPR17LMNAMAPK1MAPTGAA
SCHEMBL1826096 0.83 KMT2A (0.45) GPR17LMNAMAPTGAAG6PD
SCHEMBL1824778 0.83 GPR17 (0.47) GPR17LMNAMAPTGAAG6PD
SCHEMBL1824909 0.83 GPR17 (0.47) GPR17LMNAMAPTGAAG6PD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 GPR17 4205/4885LMNA 1802/4885MAPK1 953/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 GPR17 4459/4885LMNA 1130/4885MAPK1 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.